Louisiana Mesothelioma Victims Center Urges a Person with Mesothelioma Anywhere in Louisiana or Their Family to Focus in on Financial Compensation and To Call Attorney Erik Karst of Karst von Oiste to Get the Job Done

"We are urging a person with mesothelioma anywhere in Louisiana to call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303-for his focus on better financial compensation results. ”

— Louisiana Mesothelioma Victims Center

NEW OLEANS, LOUISIANA , USA, March 1, 2021 /EINPresswire.com/ — The Louisiana Mesothelioma Victims Center says, "We are urging a person with mesothelioma anywhere in Louisiana or their wife and or adult son-daughter to please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303-for his focus on much better financial compensation results. Erik Karst is one of the nation's most experienced mesothelioma attorneys and he and his team at Karst von Oiste consistently get the best possible financial compensation results for their clients. The typical person with mesothelioma in the United States is about 72 years old-and they will need the help of their family.

"We know that because of the nonstop barrage of information about the Coronavirus on TV and radio many people with mesothelioma were reluctant about starting financial compensation in 2020-because they did not want to expose their family to lawyers-or others who may have been infected. 2020 will probably go down as the worst year for mesothelioma compensation in twenty years-not because there were fewer people with this rare cancer-but because the Coronavirus and mesothelioma have almost identical symptoms.

"If you have just been diagnosed with mesothelioma anywhere in Louisiana please call attorney Erik Karst of the law firm of Karst von Oiste anytime at 800-714-0303. Erik Karst will make certain you receive the best possible compensation results." www.karstvonoiste.com/

The Louisiana Mesothelioma Victims Center wants to emphasize there is a statewide initiative available to a diagnosed victim anywhere in Louisiana including communities such as New Orleans, Baton Rouge, Shreveport, Lafayette, Lake Charles, Kenner, Bossier City, Monroe. https://Louisiana.MesotheliomaVictimsCenter.Com

When it comes to treatment options for mesothelioma in Louisiana the Louisiana Mesothelioma Victims Center strongly encourages diagnosed victims to contact them at 800-714-0303 for direct access to following cancer treatment centers in Louisiana, and in Texas. Note: The MD Anderson Cancer Center in Houston, Texas may be one of the most capable mesothelioma treatment centers in the world.

* Oshner Cancer Institute New Orleans:

* The MD Anderson Cancer Center Houston, Texas: https://www.mdanderson.org/

High-risk work groups for exposure to asbestos in Louisiana include Veterans of the US Navy, power plant workers, shipyard workers, maritime workers, marine mechanics, oil refinery workers, chemical plant workers, public utility workers, factory workers, plumbers, electricians, auto mechanics, machinists, and construction workers. Typically, the exposure to asbestos occurred in the 1950’s, 1960’s, 1970’s, or 1980’s. www.karstvonoiste.com/

The states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. https://Louisiana.MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health’s website related to this rare form of cancer: https://www.cancer.gov/types/mesothelioma.

Michael Thomas
Louisiana Mesothelioma Victims Center
+1 800-714-0303
email us here


Source: EIN Presswire

R3 Stem Cell and Dr. David Lawrence Greene proclaims to open Regenerative Therapy Clinic in Pakistan

Dr. David Greene is proud to announce the very first FDA-regulated and DRAP-approved Stem Cell Therapy clinic in Pakistan “R3 Stem Cell Pakistan”.

ARIZONA, UNITED STATES, March 1, 2021 /EINPresswire.com/ — Dr. David Greene and R3 Stem Cell claim the opening of a regenerative therapy/medicine clinic in Pakistan. Dr. David Greene is the pioneer behind the R3 Stem Cell. He aims to provide the best safe, and effective regenerative therapies. R3 has grown its roots to 45 clinics globally and performed more than 16,000 regenerative therapy procedures with the exosomes and Stem Cells. Under the guidance of Dr. David Lawrence Greene, we have achieved over 85% significant recovery rate with no harmful side effects.

Dr. David Greene is proud to announce the very first FDA-regulated and DRAP-approved Stem Cell Therapy clinic in Pakistan “R3 Stem Cell Pakistan” which is located in Islamabad.

Due to the advanced and cutting-edge results from Stem Cell Therapy, people are getting attention to its benefits. R3 Stem Cell Pakistan aims to provide excellent recovery rates for more than 82 diseases. Some of the common diseases include arthritis, Autism, COPD, ALS, Diabetes, Multiple Sclerosis, autoimmune disorders, erectile dysfunction, cerebral palsy, and much more.

With the countless success of European Stem Cell Treatment clinics, patients have been demanded a regenerative clinic on the Asian side of the globe. The new Stem Cell Therapy clinic in Pakistan has opened many new insights for the patients who get worried with the name of “Surgical”. The opening of this clinic will provide ease to the patients from any traveling hassle.

We believe “Don’t Operate, But Regenerate!! What about if you get yourself recovered in your own country? Sounds Cool!!

The aim behind R3 Stem Cell is to provide the best, affordable, and high-quality Stem Cell treatment. We make sure to provide cost-effective treatments to our patients. The Stem Cell experts will examine each patient in detail and suggest how much Stem Cell your condition requires. We are proud to provide Exosomes therapies as well.

In 2021, everyone is looking forward to “non-surgical”. There are proven protocols for different conditions like Diabetes, ALS, MS, Kidney failure, and many other conditions to count on. Stem Cell Treatment is contributing its major role in anti-aging.

Dr. David Greene, CEO R3 Stem Cell explains that;
“Our clinics combine extremely high-quality biologics with first-rate providers and protocols along with the world's best pricing. We offer the Mercedes of stem cell therapy for the cost of a Chevy!"

R3 Stem Cell is expanding continuously to serve its patients at the best. We provide outpatient care. You can get a free phone consultation, where the Stem Cell expert will deal with all of your queries. The number to call is (051) 8896711 or reach us at info@r3stemcell.pk

David Greene, MD, MBA
R3 Stem Cell International
email us here


Source: EIN Presswire

Intrinseque Health Announces its New Office in Taiwan

Intrinseque Health, an EN ISO 13485 certified, Global Clinical Supply Chain solutions organization is proud to announce its new office in Taipei, Taiwan

DELAWARE, UNITED STATES OF AMERICA, March 1, 2021 /EINPresswire.com/ — Intrinseque Health is proud to announce its new office in Taipei, Taiwan

Intrinseque Health, an EN ISO 13485 certified, Project Management-based, Global Drug Development Support Organization, specializing in Clinical Supply Chain solutions, has set up its new office in Taipei, Taiwan.

“This has been in the works for a long time as majority of our customers have already established their Clinical Operations in Taiwan. Intrinseque Health’s ability to source clinical supplies & medical equipment locally in-country is unparalleled in the industry. This new Taiwan setup, enables Intrinseque Health to offer more effective services to its customers in Asia Pacific region,” said, Nitin Jain, President & CEO at Intrinseque Health. This will further strengthen our clinical supply chain capabilities and introduce a wider range of drug development services,” Mr. Jain added.

“Taiwan is a key market for Intrinseque Health and we are very proud of this development, as this further certifies Intrinseque Health a trustworthy business partner capable in building and executing robust clinical supply plans for its customers’ clinical development programs,” said Kaiwei Lin, Executive Vice & General Manager, Taiwan at Intrinseque Health. “The company will offer all its services from this office, which will serve its global and local clients. ,” Ms. Lin added.

About Intrinseque Health
Intrinseque Health, is an EN ISO 13485:2016 certified, Quality Driven, Project Management-based, Global Drug Development Support organization, specializing in Clinical Supply Chain solutions.

Intrinseque Health is an expert in solving supply chain challenges like, product availability and lead time, selecting strategy for in-country sourcing or import, import regulations and IOR requirements, storage, installation, calibration, validation, servicing & maintenance of equipment and supplies. Intrinseque Health engages early with its clients to ensure each supply plan is pressure tested, as the smallest flaw in the strategy may result in study delay or even loss of patient. Every item, no matter how big or small, needs to be available at site at the time of patient visit.

Contact
Dayana Yacob
Executive Director, Global Business Operations
Email: contact@intrinsequehealth.com

Web: www.intrinsequehealth.com

Dayana Yacob
Intrinseque Health
+65 8700 4270
email us here

INTRINSEQUE HEALTH BUILDING A ROBUST CLINICAL SUPPLY PLAN


Source: EIN Presswire

Maryland US Navy Veterans Mesothelioma Advocate Recommends Attorney Erik Karst of Karst von Oiste for a Navy Veteran with Mesothelioma Anywhere in Maryland or Their Family-Get the Best Possible Compensation Results

"We do not want a Navy Veteran with mesothelioma in Maryland rolling the dice on a local car accident attorney when they can have direct access to attorney Erik Karst of Karst von Oiste. ”

— Maryland US Navy Veterans Mesothelioma Advocate

BALTIMORE , MARYLAND, USA, March 1, 2021 /EINPresswire.com/ — The Maryland US Navy Veterans Mesothelioma Advocate is recommending attorney Erik Karst of the law firm of Karst von Oiste to a Navy Veteran who has just been diagnosed with mesothelioma anywhere in Maryland. Erik Karst is one of the nation's most capable mesothelioma attorneys and he has been assisting Veterans with mesothelioma for decades. Frequently a mesothelioma compensation claim for a Navy Veteran might exceed a million dollars. As Erik Karst of the law firm of Karst von Oiste is always happy to discuss anytime at 800-714-0303 mesothelioma compensation for a Navy Veteran is most often based on how, where and when they were exposed to asbestos. The average age for a person with mesothelioma in the US is about 72 years old. www.karstvonoiste.com/

The Advocate says, "We are also appealing to the family of a Navy Veteran with mesothelioma to get involved and to help their loved one. One huge help would not be signing up for 'free' booklets, kits, guides, or calculators unless you want your loved one to be hounded day and night by lawyers you have never heard of before. If a Navy Veteran with mesothelioma in Maryland or their family want their questions answered about mesothelioma compensation-please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303. We think you will be glad you did." www.karstvonoiste.com/

The US Navy Veterans Mesothelioma Advocate offers their free services to US Navy Veterans with mesothelioma in Baltimore, Frederick, Gaithersburg, Bowie, Rockville, Hagerstown, Annapolis or anywhere in Maryland. https://Maryland.USNavyMesothelioma.Com

For the best possible mesothelioma treatment options in Maryland the Maryland US Navy Veterans Mesothelioma Advocate strongly recommends the following heath care facilities with the offer to help a diagnosed victim, or their family get to the right physicians at these hospitals.

National Cancer Institute Bethesda, Maryland:
https://www.cancer.gov/about-cancer/treatment.
* Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland:
https://www.hopkinsmedicine.org/
* University of Maryland Marlene and Stewart Greenebaum Cancer Center Baltimore, Maryland:
https://umm.edu/programs/cancer

About one third of all US citizens diagnosed with mesothelioma each year are Veterans of the US Navy. Before a Navy Veteran with mesothelioma or their family retain the services of a lawyer or law firm, they are urged to call the US Navy Veterans Mesothelioma Advocate anytime at 800-714-0303. https://USNavyMesothelioma.Com

The states with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, based on the calls the US Navy Veterans Mesothelioma advocate receives a US Navy Veteran diagnosed with mesothelioma could live in any state including New York, Florida, California, Texas, New Hampshire, Vermont, Iowa, Indiana, Missouri, Kentucky, Tennessee, North Carolina, Georgia, Alabama, Mississippi, Oklahoma, Arkansas, Nebraska, North Dakota, Montana, Wyoming, Colorado, Nevada, New Mexico, Utah, Arizona, Idaho, or Alaska. www.karstvonoiste.com/

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: https://www.cancer.gov/types/mesothelioma.

Michael Thomas
Maryland US Navy Veterans Mesothelioma Advocate
+1 800-714-0303
email us here


Source: EIN Presswire

High Incidence Of Unintended Pregnancies Drives The Oral Contraceptive Pills Market

Oral Contraceptive Pills Market Report 2021: COVID-19 Growth And Change

Oral Contraceptive Pills Global Market Report 2021: COVID-19 Growth And Change

The Business Research Company’s Oral Contraceptive Pills Global Market Report 2021: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, March 1, 2021 /EINPresswire.com/ — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Read More On The Global Oral Contraceptive Pills Market Report: https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

The high incidence of unintended pregnancies is expected to drive the growth of the generic oral contraceptive pills market over the coming years. An unintended pregnancy is a pregnancy that is always unwanted, such as a pregnancy where no children have been planned. The University of California, San Francisco (UCSF) study shows that the rates of unwanted pregnancy and abortion declined substantially when women received a one-year prescription of oral contraceptives. According to the World Health Organization (WHO), 74 million women living in low middle-income economies register unplanned pregnancies every year globally. The WHO’s research noticed 4,794 women had an unplanned pregnancy after they had discontinued using contraceptives. Therefore, the need to avoid unintended pregnancies drives the growth of the oral contraceptive pills market.

The global oral contraceptive pills market size is expected to grow from $16.51 billion in 2020 to $18.36 billion in 2021 at a compound annual growth rate (CAGR) of 11.19%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The contraceptive drugs market is expected to reach $95.04 billion in 2025 at a CAGR of 7.63%.

The oral contraceptive pills market by type into combination, progestin only, others, by category into generic, branded, by distribution channel into hospital pharmacy, retail pharmacy, clinics, online channel, public channel and NGO, others.

The major players covered in the global oral contraceptive pills market are Teva Pharmaceutical Industries Ltd, Bayer AG, Syzygy Healthcare, Mankind Pharma Ltd., Pfizer Inc., Piramal Enterprises Ltd., Ferring B.V, Merck & Co. Inc., Johnson & Johnson, Lupin Pharmaceuticals Inc, V Care Pharma, HLL Life Care, Sopharma AD, Sanofi S.A., Amneal Pharmaceuticals LLC, Abbvie Inc. (Allergan PLC), Aurobindo Pharma Limited.

Oral Contraceptive Pills Global Market Report 2021: COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides oral contraceptive pills market overview, forecast oral contraceptive pills market size and growth for the whole market, oral contraceptive pills market segments, and geographies, oral contraceptive pills market trends, oral contraceptive pills market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Oral Contraceptive Pills Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=3900&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Hormonal Contraceptives Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

Fetal And Neonatal Monitoring Devices Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/fetal-and-neonatal-monitoring-devices-global-market-report

Gynecologists Global Market Report 2018
https://www.thebusinessresearchcompany.com/report/gynecologists-global-market-report-2018

Family Planning Centers Global Market Report 2018
https://www.thebusinessresearchcompany.com/report/family-planning-centers-global-market-report-2018

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Bayer AG’s Exposure to Roundup Weedkiller Lawsuits Remains as Trial Lawyers Vow to Continue Fight for Cancer Victims

Dallas law firm representing more than 4,000: Roundup settlement inadequate for thousands sickened by glyphosate-based herbicide 

Bayer AG (OTCMKTS:BAYRY)

Bayer is trying to turn its back on thousands who became gravely ill after being exposed to Roundup. We will not let that happen, as a coalition of law firms will continue to press forward to trial.”

— Trial Lawyer Majed Nachawati

DALLAS, TEXAS, UNITED STATES, March 1, 2021 /EINPresswire.com/ — Bayer AG (OTCMKTS: BAYRY), the maker of Roundup weedkiller, had hoped a proposed multibillion-dollar partial settlement would end massive legal exposure to pending cancer claims. However, efforts by the company to resolve lawsuits for pennies on the dollar mean one thing — thousands of cancer victims and their lawyers will continue to press forward seeking justice at trial. 

Dallas-based Fears Nachawati Law Firm represents more than 4,000 individual plaintiffs in active litigation against Bayer and continues to investigate new claims on behalf of those sickened after exposure to Roundup.

Rather than a comprehensive resolution framework that would address all pending lawsuits, Bayer has sought to negotiate individually with hundreds of law firms. Trial lawyers opposed to the deal say it’s an attempt to reduce liability and financial exposure and kick the can down the road, all for the sake of pleasing shareholders.

According to published reports, law firms appointed to leadership in the federal multidistrict litigation reached separate agreements that were higher and materially disproportionate to offers for thousands of still-pending lawsuits.

“Bayer is trying to turn its back on thousands who became gravely ill after being exposed to Roundup,” said Dallas attorney Majed Nachawati of the Fears Nachawati Law Firm. “We will not let that happen, as a coalition of law firms will continue to press forward to trial.”

Roundup’s active ingredient, glyphosate, has been linked in published reports to the development of non-Hodgkin’s lymphoma and other forms of cancer. Prior to the proposed partial settlement, juries in three separate trials heard the evidence and returned multimillion-dollar verdicts against Bayer, which acquired the ownership rights to Roundup when it purchased Monsanto in 2018. 

Trial lawyers opposed to the settlement have also voiced criticism of a related lawsuit filed by class-action lawyer Elizabeth Cabraser that would limit the rights of personal injury victims to pursue future damages claims. Bayer continues to sell Roundup, and individuals who fall ill after exposure to the product should be allowed to pursue legal action.

“Bayer’s lawyers have seen what happens when juries hear this evidence,” Mr. Nachawati said. “They think they can get away with this treatment because the pandemic has delayed the ability for cancer victims to go to trial. We will not let that happen without a fight—plain and simple. We will continue to oppose any effort to limit the rights of each individual claimant to get to trial.” 

Dallas-based Fears | Nachawati Law Firm represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation.  For the past three years, the law firm was ranked number one nationally in product liability filings in federal court. For more information, visit https://www.fnlawfirm.com/.

The MDL case is In re Roundup Products Liability Litigation, case number 3:16-md-02741, in the U.S. District Court for the Northern District of California.

John Raggio
Fears Nachawati
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Elevated Demand For Mini C-Arms Devices Boosts Surgical Imaging Arms Market Growth

Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change

Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change

The Business Research Company’s Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, March 1, 2021 /EINPresswire.com/ — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Read More On The Global Surgical Imaging Arms Market Report: https://www.thebusinessresearchcompany.com/report/surgical-imaging-arms-global-market-report

High demand for mini-C-arms devices is expected to boost market growth during the forecast period. Globally, companies are engaged in the development and manufacturing of novel equipment that assists surgeons in carrying out surgical procedures smoothly and efficiently. The rising demand for mini C-arms devices can be attributed to features such as its miniaturized size, easy adaptability in the operation theatre, and lower price than other types of C-arms. For instance, in January 2018, Hologic, Inc. launched the next generation mini C-arm imaging, the Fluoroscan InSight FD Mini C-Arm. On an intuitive 24-inch HD touchscreen, the device delivers the largest image size and highest image resolution available with the help of features such as high-resolution and low-dose-rate modes. In September 2019, OrthoScan Inc. launched TAU 2020 Mini C-arm which introduces the largest screen on the mini C-arm.
Minimally invasive tests or surgeries incur low costs and saves between $280 million and $340 million in the USA alone by opting for it. With this, the doses can be saved by minimizing shots to enhance work efficiency. Thus, the rising demand for mini C-arms combined with its easy-to-use features is expected to drive the market growth.

TBRC’s surgical imaging systems market report is segmented by product type into G-arm surgical imaging devices, C-arm surgical imaging devices, O-arm surgical imaging devices; by technology into image intensifier C-arms, flat panel detector C-arms; by application into orthopaedic and trauma surgeries, neurosurgeries, cardiovascular surgeries, gastrointestinal surgeries, other applications; by end-user into hospitals and ambulatory surgical centers, academic research institutes.

The global surgical imaging arms market size is expected to grow from $1.08 billion in 2020 to $1.19 billion in 2021 at a compound annual growth rate (CAGR) of 10.41%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.40 billion in 2025 at a CAGR of 4.20%.

Surgical imaging arms industry analysis shows the major players in the market to be GE Healthcare, Hologic Inc., ATON GmbH, Whale Imaging Inc., Siemens Healthcare, Shimadzu Corp., Canon Medical Systems Corporation, Medtronic plc, Ziehm Imaging, Philips Healthcare, Eurocolumbus, GENORAY Co. Ltd., Allengers Medical Systems, Orthoscan, Hitachi.

Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides surgical imaging arms market overview, forecast surgical imaging arms market size and growth for the whole market, surgical imaging arms market segments, and geographies, surgical imaging arms market trends, surgical imaging arms market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Surgical Imaging Arms Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=3902&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Surgical Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/surgical-equipment-global-market-report-2020-30-covid-19-impact-and-recovery

ENT Surgical Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/ent-surgical-devices-and-equipment-global-market-report

3D Medical Imaging Market Global Report 2020-30: Covid 19 Growth and Change
https://www.thebusinessresearchcompany.com/report/3d-medical-imaging-market-global-report-2020-30-covid-19-growth-and-change

Nuclear Imaging Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/nuclear-imaging-devices-and-equipment-global-market-report

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Zhimeng Biopharma Announces Global Partner Search for its' Development of a Cure for Chronic Hepatitis B Virus Infection

Image of Hepatitis B Virus, a global infectious disease pathogen

Zhimeng Biopharma is a leading Chinese developer of an anti-Hepatitis B drug

Zhimeng Biopharma is developing ZM-H1505R, an oral Hepatitis B Virus capsid formation inhibitor, for treating patients with chronic hepatitis B virus infection.

ZM-H1505R has the potential to become the leader in curing chronic hepatitis B, a very large and unmet medical need.”

— Dr. Huanming Chen

SHANGHAI, CHINA, March 1, 2021 /EINPresswire.com/ — Following a strategic review of its clinical and commercial development options, Zhimeng Biopharma (“Zhimeng”; http://core-biopharma.com) has appointed The Sage Group (New York and London) to lead the partnering program for its leading drug candidate, ZM-H1505R.

Zhimeng is developing ZM-H1505R, a patented, orally-administered, investigational Hepatitis B Virus (HBV) capsid formation inhibitor, for treating patients with chronic hepatitis B (CHB) virus infection which afflicts 250 million people worldwide.

Zhimeng is a start-up biotech founded in Shanghai, China in 2017 by seasoned pharmaceutical industry veterans (ex- Sanofi, Medicilon, Simcere, Valeant, BioDuro).

In China, the disease burden of HBV is the highest among communicable diseases, and about 10 million people living with chronic HBV will die by 2030. Worldwide, hepatitis B results in 887,000 deaths annually, and chronic infection cases continue to accrue. Of these, about 300,000 deaths are due to liver cancer.

Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop. Cirrhosis or liver cancer occurs in about 50-60% of those with chronic liver disease.

Currently available therapeutic options for HBV drive a ~$2.5 billion global market.

The hepatitis B virus (HBV) capsid or core protein (Cp) is now being pursued as a target for small-molecule antivirals that enhance the rate and extent of its assembly to yield empty and/or faulty, aberrant capsids. These small molecules represent a promising treatment for suppression of HBV, and are the focus of the development work conducted by Zhimeng.

ZM-H1501R is a novel molecule with a pyrazole structure. It inhibits HBV replication by accelerating the formation of defective virus capsid and is competitively well positioned: the molecule has superior potency and is active against mutant viruses that are resistant to other capsid inhibitors.

Zhimeng has successfully completed a Phase 1A study in the USA and is planning to conduct an 1b study in HBV-infected patients in China in March 2021, leading to a Phase 2 study to be conducted starting in 2022.

Zhimeng is seeking a global partner for ZM-H1501R to facilitate clinical and commercial development of this exciting new drug.
Zhimeng has long lasting and issued patents protecting its discoveries and its pipeline.

Dr. Huanming Chen, CEO of Zhimeng, said “ZM-H1505R has the potential to become the leader in curing chronic hepatitis B, a very large and unmet medical need.”

For more information about Zhimeng Biopharma and partnering opportunities for its pipeline drug candidates, please contact:

Dr. Bill Mason
The Sage Group
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX UK
Tel: +44 (0) 7785 950134
wtm@sagehealthcare.com

Or

Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North
#381 Clinton
New Jersey 08809 USA
Phone: +1 908 2306170
wpambianchi@sagehealthcare.com

Or

Dr. Huanming Chen or Dr. Zhijun Zhang
hchen@corebiopharma.com or zzhang@corebiopharma.com
http://core-biopharma.com

About Zhimeng Therapeutics
Shanghai Zhimeng Biopharma Inc. (Zhimeng) is a start-up biotech founded in 2017 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with great unmet medical needs.

Realizing the complexity of the pathogenesis of chronic hepatitis HBV infection, Zhimeng has adopted a comprehensive approach to tackle the diseases by directly targeting the hepatitis B virus (HBV) with multiple pronged attacks, as well as through restoring the host immune systems. Zhimeng’s goal is to deliver innovative, most effective, safe and affordable therapies to bring a cure for patients suffering from CHB.

Zhimeng is also actively developing novel small molecule drugs to treat neurological diseases, such as epilepsy, pains and strokes. Zhimeng’s goal is to provide novel and more effective medicines to improve the quality of life of patients with such diseases.

Website: http://core-biopharma.com/

About The Sage Group, Inc.
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.

The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.

The range of services offered includes:
• Strategic alliances and licensing/partnering
• M&A, divestment, buy- and sell- side
• Global product and technology acquisition searches
• Strategic assessment and planning
• Due diligence, technology and molecule assessment, valuation
• New ventures, interim management
• Facilitating investment in R&D and/or company equity through introductions, network and brokering

The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.

Website: www.sagehealthcare.com

Dr. Bill Mason
The Sage Group
+44 7785 950134
email us here


Source: EIN Presswire

International research collaborations from the new partnership between Kobe University, Japan, and Fourier Intelligence

From top left: Associate Professor Sasithorn Sung-U, Professor Hisafumi Yasuda, Mr Zen Koh, Associate Professor Tomoko Uchida, and Professor Rumi Tanemura. From bottom left: Ms Hayley Lim, Mr Owen Teoh, and Ms Sarah Lim.

From top left: Associate Professor Sasithorn Sung-U, Professor Hisafumi Yasuda, Mr Zen Koh, Associate Professor Tomoko Uchida, and Professor Rumi Tanemura. From bottom left: Ms Hayley Lim, Mr Owen Teoh, and Ms Sarah Lim.

The HandyRehab™ hand exoskeleton on the OTParvos™ digital smartboard.

The HandyRehab™ hand exoskeleton on the OTParvos™ digital smartboard.

Fourier Intelligence’s RehabHub™

Fourier Intelligence’s RehabHub™

This partnership aims to promote advanced rehabilitation technology and integrate group therapy into the clinical setting.

We’re delighted to be able to forge this new partnership with Kobe University to introduce previously research-oriented projects on rehabilitation robotics into clinical settings.”

— Mr Zen Koh, Fourier Intelligence’s Global Hub Chief Executive Officer

SINGAPORE, March 1, 2021 /EINPresswire.com/ — Fourier Intelligence has started a new partnership with Kobe University, Japan. This partnership signifies Fourier Intelligence’s global vision in promoting accessibility and adoption of rehabilitation technology. For Kobe University, this is the continuation to integrate education, research, and technology to support clinicians in delivering top-quality rehabilitation services.

The global rehabilitation robots market size was valued at USD 529.8 Million in 2018 and is projected to reach USD 2,617.3 Million by 2026, exhibiting a CAGR of 22.1% during the forecast period. This is according to market research firm Globe Newswire. Demand for rehabilitation robots is expected to be very strong in Japan, given its rapidly greying and shrinking population.

Rehabilitation robots are expected to help the elderly regain their independence of daily living and avoid becoming bed ridden. Robotics can also enable patients to train independently and with minimum clinician intervention. This could be a major incentive for countries facing the dwindling population of working-age people who must care for the increasingly mushrooming number of retirees. By 2035, it is estimated a third of Japan’s population would be aged 65 or older.

Therefore, this partnership comes in timely to address rehabilitation needs for the elderly and neurorehabilitation patient populations. Professor Rumi Tanemura from the Department of Rehabilitation Science would be leading the research efforts for this partnership. The research would focus on Fourier Intelligence’s Upper Limb RehabHub™ series, introducing translational research into the clinical setting. The partnership would focus on the portable finger rehabilitation glove, the HandyRehab™, paired with the digital smartboard, OTParvos™.

“We’re delighted to be able to forge this new partnership with Kobe University, which is one of the highest-ranked universities in Japan,” said Mr Zen Koh, Fourier Intelligence’s Global Hub Chief Executive Officer. “This collaboration aims to introduce previously research-oriented projects on rehabilitation robotics into clinical settings. This will tremendously improve the efficiency of clinical services for clinicians and resulting in better clinical outcomes for patients.”

“We are excited in this partnership with Fourier Intelligence and to join their global research network in introducing advanced rehabilitation technology for Japan’s rehabilitation services,” said Professor Rumi Tanemura. “We believe this is mutually beneficial, as Kobe University trains some of the best therapists in Japan and combining our in-depth clinical knowhow, we can jointly develop technologies that will be highly relevant for our hospitals.”

The Memorandum of Understanding signing event took place virtually on the 24th of February with Professor Hisafumi Yasuda, Dean of the Graduate School of Health Sciences, Kobe University and Mr Zen Koh. The signing was witnessed by Kobe University’s Professor Rumi Tanemura, Associate Professor Tomoko Uchida, and Associate Professor Sasithorn Sung-U from Chiang Mai University. From Fourier Intelligence, Mr Owen Teoh, General Manager, Ms Hayley Lim, Assistant Business Development Director and Ms Sarah Lim, Senior Manager of Clinical Applications and Scientific Research attended the virtual event.

The partnership will focus on efficacy research on upper limb robotics for patients. Ultimately, the partnership will collaborate on multi-centre trials that will involve Fourier Intelligence’s extensive global network of researchers and laboratories.

Kerry GUO (Ms)
Fourier Intelligence
+65 6911 6651
kerry.guo@fftai.com
Visit us on social media:
Facebook
Twitter
LinkedIn

Fourier Intelligence’s HandyRehab™


Source: EIN Presswire

Where Did The Name Healthy1Inc Come From?

Business Owner Of Healthy1inc

The day he believed it was possible to start Healthy1Inc.

The Dream Came True

Enjoy Living Life Healthy

#lifestyle #choices #discipline

A Symbol To Remember, A Household Brand.

All I Needed Was Job Which Soon Became A Career And Evolved Into A Lifestyle. Best Thing That Ever Happened.

CASSELBERRY, FLORIDA, UNITED STATES, March 1, 2021 /EINPresswire.com/ — Healthy1Inc Owner Matthew Zifferblatt recalls the past events that led to him starting the company.

Flash back to August 10th, 2017: The day it all began. I was unemployed and about to launch my own supplement brand. My passion to help others needed to be funneled into something productive to provide for my family. My body was out of shape; I was about 90 pounds overweight and only had about $2,000 in my pocket to begin this venture. I decided to take a huge personal risk and jump headfirst into the unknown. On this day, the company was born. Eventually it would grow to a brand, and finally a lifestyle.

Every new company needs a name, right? That is always a challenge. My goals were to improve personal health, I knew I needed to change, to get healthier, and through this new brand, bring about change in others’ physical and mental health. After a few late-night brainstorming sessions, a theme was starting to come together.

The name came from the change that was coming for me and what I wanted to deliver to the public: I wanted them to be Healthy, I wanted to be the Healthy One. And that is how it dawned on me, Healthy1! And so it began. Now, here we are 4 years later and the name Healthy1Inc has dominated in the nutrition industry from its inception. We are proud to be a well-known brand that people know and trust. The name Healthy1Inc has meaning – and a mission.

What Does Healthy1Inc Stand For?

“Healthy1inc began as a job, because that’s exactly what I needed at the time” said owner Matthew Zifferblatt.
However, it did not remain as a simple “job”. As I was struggling to lose weight, I began to incorporate new core values into my routine to better push through to the next weight loss milestone. These values became instilled in my brand, Healthy1Inc, and through them I have been able to set a standard for helping others with their personal health goals.

The first value: Lifestyle – Our lifestyle needs to change to stay and remain healthy. To be the Healthy1 is to incorporate a completely new lifestyle.

The second value: Choices – are the things we all must wrestle with in life. Making the right choices is vital for personal health.

The final value: Discipline – because without discipline we just have a dream. Everyone can learn the discipline that is required to uphold a healthy lifestyle. It’s achieved by adhering to the first two values.

Today, Healthy1Inc stands for #lifestyle #choices #disclipine

Why Coaching?
Since my 90 pound weight loss transformation and struggle it became known to me that most people didn’t have a lot of knowledge or training – many were just as stuck as I felt with my excess weight. They had no plan to lose it, but knew something had to be done about it.

From that realization, I began to offer personal coaching services through Healthy1Inc. This was something I felt called upon to do. My personal success can be a motivator for you – and together we can accomplish greater things than either could alone. That’s the power of a strong bond with a coach. And that’s what I’m proud to provide here at Healthy1Inc. Since 2017 I’ve helped hundreds of people achieve their personal health goals through one-on-one coaching. And every day I’m proud to say I am making a difference with my brand.

Sincerely,

Matthew Zifferblatt
Owner & Operator
Healthy1Inc

To learn more about this company, hire a personal health coach, or purchase some all-natural supplements, please contact us below:

Healthy1Inc
360 Wilshire Plaza
Casselberry, FL 32707
info@healthyoneinc.com
www.healthyoneinc.com
http://matthewhere.com/

#lifestyle #choices #discipline

Matthew Zifferblatt
healthy1inc
+1 407-613-2823
email us here
Visit us on social media:
Facebook
LinkedIn


Source: EIN Presswire